New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
13:11 EDTGILDGilead March volatility elevated as shares pullback to two-month low
Gilead March call option implied volatility is at 38, April is at 35, May is at 38, August is at 37; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 2, 2016
16:01 EDTGILDGilead reports Q4 total product sales $8.4B
Total product sales for the fourth quarter of 2015 were $8.4B compared to $7.2B for the fourth quarter of 2014. In the fourth quarter of 2015, product sales in the U.S. were $4.8B compared to $5.5B in the fourth quarter of 2014. In Europe, product sales were $1.7B compared to $1.4B in the fourth quarter of 2014. Sales in other international locations increased to $1.9B compared to $373M in the fourth quarter of 2014, primarily due to sales of Sovaldi(R) (sofosbuvir 400 mg) and Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) in Japan.
16:00 EDTGILDGilead reports Q4 adjusted EPS $3.32, consensus $3.00
Subscribe for More Information
14:32 EDTGILDNotable companies reporting after market close
Subscribe for More Information
12:33 EDTGILDGilead February weekly 83 straddle priced for 6% movement into Q4
11:52 EDTGILDGilead technical notes before earnings news
There is an active bearish head and shoulders pattern on the daily chart that became active when price broke below $93. Downside potential for the pattern, if it remains active and completes, is to the $65 to $62.50 area over time. If the news is bearish, the pattern is likely to continue to develop. If the news is a bullish surprise, it is possible that the pattern will become inactive if price can rise above $93. To void the pattern entirely would take a move above $110.
09:46 EDTGILDIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
February 1, 2016
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open: BAC AAPL FB AMZN TWTR MGM MCD NFLX GILD INTC TSLA AA BABA C
09:23 EDTGILDGilead volatility elevated into Q4 and outlook
Gilead February weekly call option implied volatility is at 62, February is at 44, March is at 38; compared to its 52-week range of 22 to 49, suggesting large near term price movement into the expected release of Q4 results on February 2.
09:05 EDTGILDGilead says EMA validates Type II variation application for Truvada
Subscribe for More Information
05:17 EDTGILDStocks with implied volatility movement; GILD PBR
Subscribe for More Information
January 29, 2016
17:12 EDTGILDOn The Fly: Top stock stories for Friday
Stocks began the session in positive territory and remained there throughout the day. The early strength was attributed to the surprise cut in interest rates by the Bank of Japan that put the country in a negative interest rate scenario. The market gained strength throughout the day and put in gains of almost 2.5% in what was a broad based advance for the major averages. January closed out with two winning weeks, but the month was still a very bad one for stocks, as the S&P lost over 5% even after today's strong showing. ECONOMIC EVENTS: In the U.S., the Commerce Department's first read on fourth quarter gross domestic product came in at 0.7% annualized growth, below the already anemic 0.8% growth forecast. The Chicago PMI business barometer bounced to 55.6 in January, topping forecasts for a 45.3 reading. The University of Michigan consumer sentiment index slipped to 92.0 in the final January print, missing the 93.0 reading that was forecast. In a surprise move in Asia, the Bank of Japan introduced a rate of minus 0.1% on certain excess holdings of cash while maintaining the pace of its asset purchases. Japan also reported data pointing to a softening economy, as total CPI grew 0.2% year-over-year in December, core CPI rose at only a 0.1% pace and industrial production fell a preliminary 1.4% month-over-month in December. COMPANY NEWS: Shares of Amazon (AMZN) declined 7.6% to $587 after the company's fourth quarter results came in below expectations. Meanwhile, Microsoft (MSFT), which reported better than expected earnings after last night's closing bell, gained 5.8% to $55.09... Confirming a news report that broke late in the day yesterday, Xerox (XRX) announced plans to separate into two independent publicly-traded companies: one focused on Document Technology and another Business Process Outsourcing company. Xerox also announced an agreement related to the governance of the Business Process Outsourcing company under which six directors of the new company will be selected by Xerox and three will be selected by current Xerox shareholder Carl Icahn... Chevron (CVX) reported a quarterly loss due to taking impairments and other charges of $1.1B. The company, which also reported that its average sales price per barrel of crude oil and natural gas liquids in the U.S. was $35 in fourth quarter, down from $66 a year ago, edged up 0.7% to $86.44. MAJOR MOVERS: Among the notable gainers was Axiall (AXLL), which jumped 83% to $17.94 after it came to light that the company received, and rejected, an unsolicited proposal from Westlake Chemical (WLK) offering to acquire the company for $20 per share in cash and stock. Also higher were Visa (V) and Mastercard (MA), which gained 7% and 6.4%, respectively, after reporting quarterly earnings. Among the notable losers was Gilead (GILD), which fell 5.5% to $82.70 after rival Merck (MRK) received FDA approval for its own hepatitis C drug. Also potentially weighing on Gilead shares was the fact that competitor AbbVie (ABBV) announced financial results for the fourth quarter, including sales of Viekira Pak, its own hep C treatment, that fell short of estimates. AbbVie fell 2.3% to $54.58 following its quarterly report. INDEXES: The Dow rose 396.66, or 2.47%, to 16,466.30, the Nasdaq gained 107.28, or 2.38%, to 4,613.95, and the S&P 500 added 46.88, or 2.48%, to 1,940.24.
16:00 EDTGILDOptions Update; January 29, 2016
Subscribe for More Information
13:19 EDTGILDOptions with increasing call volume: EXP FLIR SYN INO PBR VMEM EPI GILD EA
Subscribe for More Information
10:16 EDTGILDOptions with increasing implied volatility: WMB W CERS RAD CRM GILD MNST
Subscribe for More Information
09:44 EDTGILDGilead slips as another drug enters Hepatitis C virus space
Shares of Gilead (GILD), a leader in the hepatitis C virus treatment space, are sliding this morning after one competitor's hep C drug was granted FDA approval and another's sales disappointed. Additionally, Gilead reported its own news, announcing a shakeup of the roles held by its top executives. MERCK APPROVAL: Merck (MRK) announced last night that the FDA has approved Zepatier for the treatment of adult patients with chronic hepatitis C virus, or HCV, genotype, or GT, 1 or GT4 infection. Merck has established a list price of $54,600 for a 12-week regimen of Zepatier, which the company said it believes to "be in the range of net prices for other commonly used HCV direct-acting antiviral regimens at 12 weeks of therapy." In contrast, a 12-week regimen of Gilead's Sovaldi is reported to be priced at $84,000. Merck added that it anticipates that this price, as well as its "strategy to seek broad coverage across commercial and public segments," will help broaden and accelerate patient access to treatment. ABBVIE RESULTS: Meanwhile, Gilead competitor AbbVie (ABBV) announced financial results for the fourth quarter this morning. AbbVie announced Q4 sales of Viekira Pak, its own hep C treatment, of $554M, including U.S. sales of $197M and international sales of $357M. Analysts expected AbbVie to report Q4 Viekira sales of $568.5M, according to a Bloomberg consensus estimate that factored in four forecasts. EXECUTIVE CHANGES: Additionally, Gilead announced this morning that current chairman and CEO John Martin will assume the role of executive chairman, effective March 10. John Milligan, currently president and COO, will be promoted to CEO and appointed to the company's board. PRICE ACTION: In morning trading, Gilead shares slipped 3.5% to $84.50, while AbbVie fell 2.4% to $54.53 and Merck (MRK) gained 1% to $49.75.
09:35 EDTGILDGilead falls, levels to watch
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open: AMZN MSFT FB AAPL GILD GE
Subscribe for More Information
09:21 EDTGILDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Gigamon (GIMO), up 17.7%... Fortinet (FTNT), up 10%... Flextronics (FLEX), up 10%... Skyworks (SWKS), up 5.7%... Seagate Technology (STX), up 4.9%.. Microsoft (MSFT), up 4.6%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 8.1% after CEO says Zika vaccine could enter human testing this year... J.C. Penney (JCP), up 2.1% after being upgraded to Neutral from Underperform at Credit Suisse... BRF S.A. (BRFS), up 3.1% after being upgraded to Buy from Hold at Deutsche Bank... Axiall (AXLL), up 83.4% after rejecting $20 per share acquisition proposal from Westlake Chemical (WLK)... Energous (WATT), up 12% after Bloomberg reported that Apple (AAPL) is working with partners in the U.S. and Asia to develop new wireless charging technology. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.1%... Electronic Arts (EA), down 6.2%... AbbVie (ABBV), down 4%... American Airlines (AAL), down 1.3%. ALSO LOWER: Gilead Sciences (GILD), down 5.5% after CEO John Martin to assume role of executive chairman and COO John Milligan will be promoted to CEO.
08:14 EDTGILDPiper Jaffray holds an analyst/industry conference call to discuss Gilead
Subscribe for More Information
08:01 EDTGILDGilead chairman, CEO John C. Martin to assume role of executive chairman
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use